Fluad Quadrivalent Influenza Vaccine Approved for Older Adults

The FDA has approved Fluad Quadrivalent for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.

The Food and Drug Administration (FDA) has approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. 

Like Fluad (trivalent, inactivated, influenza vaccine [virus types A and B]), Fluad Quadrivalent contains the MF59 adjuvant, which is designed to enhance and prolong immune responses. The immunogenicity of Fluad Quadrivalent was confirmed in a non-influenza comparator-controlled efficacy study in which elderly patients 65 years and older (mean age: 72 years) received 1 dose of either Fluad Quadrivalent or a US-licensed non-influenza comparator vaccine. 

While the vaccine approval was accelerated based on evidence of immune response, continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.

Related Articles

Fluad Quadrivalent is expected to be available for the 2020-2021 influenza season. The product will be supplied in 0.5mL single-dose prefilled syringes. 

For more information visit seqirus.com

This article originally appeared on MPR